Epilepsy: Competitive Landscape, Market and Pipeline Analysis 2018 - Analysis of 115+ Therapeutic Drugs - ResearchAndMarkets.com

DUBLIN--()--The "Epilepsy- Competitive Landscape, Market and Pipeline Analysis, 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.

This report provides comprehensive insights about marketed and pipeline drugs across this indication. The report provides the detailed analysis of 115+ products along with 45+ companies involved. Ultragenyx Pharmaceuticals, Takeda, and Pfizer are among the developers of most promising pipeline products.

Products covered by Phase

  • Marketed Products
  • Phase III, Phase II and Phase I
  • Pre-clinical, Discovery and Unknown Phase

Overview of pipeline development activities for Epilepsy

  • Pipeline analysis of 115+ therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and non-clinical results, designations, collaborations & licensing deals, grants, technology and patent details. Report contains the development and sale activities for marketed drugs.
  • Therapeutic segmentation of products for Epilepsy
  • The report comprises of comparative pipeline therapeutics assessment by development stage, therapy type, molecule type, and administration route across this Immunotherapy.

Scope

  • The report provides competitive pipeline landscape of Epilepsy
  • The report provides the marketed drugs information including its sales, development activities and details of patent expiry
  • The report provides the insight of current and future market for Epilepsy
  • The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
  • Coverage of the Epilepsy pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
  • The report reviews key players involved in the therapeutics development for Epilepsy and also provide company profiling
  • Pipeline products coverage based on various stages of development ranging from late stage till discovery stage
  • Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Companies Mentioned

  • Acorda Therapeutics
  • Adamas Pharmaceuticals
  • Addex Therapeutics
  • Bio-Pharm Solutions
  • Biscayne Neurotherapeutics
  • Catalyst Pharmaceuticals
  • Chong Kun Dang
  • D-Pharm
  • Eisai
  • Epygenix Therapeutics
  • GlaxoSmithKline
  • Grupo Ferrer Internacional
  • GW Pharmaceuticals
  • INSYS Therapeutics
  • Marinus Pharmaceuticals
  • Neurelis
  • ORPHELIA Pharma
  • Ovid Therapeutics
  • Pfizer
  • PTC Therapeutics
  • Retrophin
  • Sage Therapeutics
  • SciFluor Life Sciences
  • Serina Therapeutics
  • SK Biopharmaceuticals
  • SK Chemicals
  • Suda
  • Takeda Pharmaceutical
  • Techfields Pharma
  • Turing Pharmaceuticals
  • UCB
  • Veritas Pharma
  • VistaGen Therapeutics
  • Xenon Pharmaceuticals
  • XERIS Pharmaceuticals

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/fmgdjz/epilepsy?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Central Nervous System Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Central Nervous System Drugs